ChargePoint Technology Industry Blog
Liverpool-based ChargePoint Technology will showcase their revolutionary device at Interphex in New York - one of the world’s biggest biopharma events for innovative manufacturers.
Will it be Clinton? Will it be Trump? Big Pharma in the US is part of the American Dream, but the world needs pioneers
The US Presidential campaign is stirring up strong feelings on issues like immigration and healthcare with the media’s spotlight trained on Republican Donald Trump – who wants to ‘Make America Great Again’.
Front-runner for the incumbent Democrats, Hillary Clinton is also spending millions pushing her key pledges to voters. She is promising to be a “small business president” which means she wants to give SMEs and entrepreneurs more access to finance, cut through red tape for start-ups and lavish tax reliefs.
When Leonardo DiCaprio won his first Oscar for his role in The Revenant he used the platform to reach a massive worldwide audience to urge more to be done to combat climate change - one of the major scientific issues of our time.
The A-lister’s comments have been well-publicised and the cause he has chosen has been a perennial warning in the media for decades.
ChargePoint Technology has passed a sterility challenge for its AseptiSafe split butterfly valve, which has been specifically designed to transfer aseptic products and components in fill/finish, biotech and sterile API production.
The spilt butterfly valve has a number of practical advantages over existing sterile transfer techniques although for years lacked the microbiological data to support its use. An indpendent study, by 3rd party SKAN AG (Basel, Switzerland), has been carried out with the aim of gathering this data by means of qualifying the technology.